Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,017 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE).
Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC Jr, Roe MT; CRUSADE Investigators. Tricoci P, et al. Among authors: cannon cp. Am J Cardiol. 2006 Nov 1;98(9):1172-6. doi: 10.1016/j.amjcard.2006.05.047. Epub 2006 Aug 31. Am J Cardiol. 2006. PMID: 17056321
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry).
Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP; REACH Registry Investigators. Steinberg BA, et al. Among authors: cannon cp. Am J Cardiol. 2007 May 1;99(9):1212-5. doi: 10.1016/j.amjcard.2006.12.039. Epub 2007 Mar 16. Am J Cardiol. 2007. PMID: 17478144
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. James S, et al. Among authors: cannon cp. Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003. Am Heart J. 2009. PMID: 19332184 Clinical Trial.
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP; REACH Investigators. Kumar A, et al. Among authors: cannon cp. Crit Pathw Cardiol. 2009 Sep;8(3):104-11. doi: 10.1097/HPC.0b013e3181b8395d. Crit Pathw Cardiol. 2009. PMID: 19726929
1,017 results